Federal Agencies
Federal Executive Branch
Here's a look at documents from the U.S. Executive Branch
Featured Stories
U.S. Space Force Launches DoW STP-S29A Mission, Delivers Experimental and Research Payloads
WASHINGTON, April 8 -- The U.S. Space Systems Command issued the following news release on April 7, 2026:* * *
U.S. Space Force launches DoW STP-S29A mission, delivers experimental and research payloads
Summary: The U.S. Space Force successfully launched the Department of War's (DoW) Space Test Program S29A (STP-S29A) mission aboard a Minotaur IV rocket from Vandenberg Space Force Base, Calif. This mission delivered the the STPSat-7 space vehicle housing five DoW experiments and additional research CubeSats into low Earth orbit (LEO).
*
EL SEGUNDO, Calif. -- The U.S. Space Force's (USSF) ... Show Full Article WASHINGTON, April 8 -- The U.S. Space Systems Command issued the following news release on April 7, 2026: * * * U.S. Space Force launches DoW STP-S29A mission, delivers experimental and research payloads Summary: The U.S. Space Force successfully launched the Department of War's (DoW) Space Test Program S29A (STP-S29A) mission aboard a Minotaur IV rocket from Vandenberg Space Force Base, Calif. This mission delivered the the STPSat-7 space vehicle housing five DoW experiments and additional research CubeSats into low Earth orbit (LEO). * EL SEGUNDO, Calif. -- The U.S. Space Force's (USSF)Space Systems Command (SSC) launched the U.S. Department of War's (DoW) Space Test Program S29A (STP-S29A) mission aboard a Minotaur IV launch vehicle from Space Launch Complex 8 at Vandenberg Space Force Base, Calif., at 4:33 a.m. PDT, April 7, 2026.
This flight was the second STP mission to launch in four months, highlighting SSC's continuing efforts to develop and test new technologies leading to the next generation of space capabilities. The DoW's STP, managed by SSC's System Delta 89 (SYD 89), will oversee on-orbit operations.
The primary payload aboard the mission was STPSat-7, an Evolved Expendable Launch Vehicle (EELV) Secondary Payload Adapter (ESPA) class satellite designed and built by the DoW Space Test Program (STP). DoW STP is headquartered at Kirtland Air Force Base, New Mexico, with an Operating Location at the National Aeronautics and Space Administration's (NASA) Johnson Space Center in Houston, Texas.
The co-prime on this mission is a pair of U.S. Army-sponsored CubeSats called Rawhide. Secondary payloads onboard are MISR-C, CANVAS, AggieSat6, and ASTRA-HyRAX. DoW-STP plays a critical role in advancing space technology by providing experimental demonstration opportunities and rapid access to space for research and development projects.
"The successful launch of STP-S29A directly answers the call for a stronger, more capable military and underscores the critical role of the Space Force in deterring future conflicts," said USSF Lt. Col. Brian Shimek, system program manager and director for STP. "The space domain is where we can and must maintain our strategic advantage. This mission is a clear demonstration of that principle in action."
"The advanced experiments on board will provide invaluable data, enhance our space domain awareness, and ensure we continue to outpace our adversaries," said Shimek.
The launch service was procured and led by SSC System Delta 80's (SYD 80) Small Launch and Targets Division under its the Rocket System Launch Program (RSLP), which the department's dedicated organization for small experimental, test, target, and responsive launch solutions.
"This launch, made possible through our strong partnership with the Rocket System Launch Program, is a vital step in building the next generation of space capabilities required to secure our nation's future. I am extremely proud of the team that executed this mission with the sense of urgency our strategic environment demands."
With multiple pathways to efficiently launch capability on orbit, RSLP has supported more than 740 launches to date.
"Fantastic launch today from Vandenberg Space Force Base with our Space Test Program, Northrop Grumman, and SLD 30 teammates," said USSF Lt. Col. Steve Hendershot, system program manager for RSLP. "Every mission has its unique challenges, and this one is no exception, and it's a thrill to tackle them from mission design to spacecraft separation,"
Hendershot added that the launch profile was adapted for payload composition, trajectory, and a very specific separation timing to satisfy the individual satellite needs.
"It's highly technical, exciting, and is what attracts talented folks to the Space Force...and being part of a successful launch that delivers capability on orbit is our reward," Hendershot said.
RSLP used the Orbital Services Program (OSP-4), a highly flexible Indefinite Delivery, Indefinite Quantity (IDIQ) contract used to provide launch services for military payloads over 400 lbs. to any orbit.
"RSLP launches from sites around the globe, including Pacific Spaceport Complex-Alaska at Kodiak, MARS at Wallops Flight Facility in Virgina, Cape Canaveral and here at Vandenberg...we can launch wherever, whenever the mission needs," said Sean Mussell, RSLP's STP-S29A mission manager.
Northrop-Grumman is the launch service contractor and is responsible for providing the Minotaur IV launch service for the STP-S29A mission. The initial value of the launch service was $29.9M when awarded in September 2022. The last Minotaur IV launch occurred one year prior, also from SLC-8 at Vandenberg.
The STP-S29A mission is the 308th mission for DoW's STP. Throughout its 58-year history STP missions have supported the development of technology behind all critical Space Force capabilities such as satellite communications, positioning, navigation, and timing, space sensing, space domain awareness, and space access.
Once on orbit, the Space Test Program will operate STPSat-7 from Johnson Space Center, Houston, TX. The spacecraft was developed using common platform avionics deployed to the International Space Station in their H-series missions as well as using commercial ground antenna infrastructure. The five experiments comprising the mission are:
* The Naval Information Warfare Centers' NanoUHF Comms will demonstrate military SATCOM capability for proliferated Low Earth Orbit (pLEO) constellations. It will provide crucial beyond-line-of-sight (BLOS) communication and message broadcast services, significantly extending the operational reach of naval forces. A key innovation is the payload's ability to perform real-time Doppler compensation while in orbit. This feature allows existing Navy radio systems to seamlessly connect with LEO satellites, overcoming the frequency shifts caused by high-speed satellite movement.
* The Naval Research Laboratory's Laser-sheet Anomaly Resolution and Debris Observation (LARADO) instrument will detect and characterize small orbital debris that cannot be observed from the ground. LARADO is funded and managed by the Helio physics Division's nascent Orbital Debris and Space Situational Awareness activity within NASA's Science Mission Directorate.
* The Naval Research Laboratory's GNSS Orbital Situational Awareness Sensor (GOSAS) is a CubeSat-compatible, programmable dual GPC receiver designed to characterize the orbital GNSS environment and produce high quality ionospheric space weather products.
* The Naval Research Laboratory's GAgg Radiation Instrumentation-1C (GARI-1C) follows the GARI program in the goal of space qualifying the Gd3(Al,Ga)O12 (GAGG) scintillator for space-based defense applications. The detector technology offers improved energy resolution, lower power consumption and reduced size compared to similar systems. The experiments represent teamwork across the services, and stem from a collaboration between the DoW Space Test Program, the U.S. Naval Research Laboratory (NRL), Naval Information Warfare Center- Pacific (NIWC-PAC), and the Air Force Research Laboratory (AFRL).
* The co-prime payload in addition to STP-Sat7 on S29A is a payload that goes by the name of Rawhide. Rawhide continues the legacy of the United States Army Space and Missile Defense Command (USASMDC) Technology Center mission to develop and transition advanced tactical space support capabilities and concepts to the warfighter.
Secondary payloads, once in orbit, will be operated via their respective sponsors and serve a myriad of defense and academic research programs:
* The Department of War's MISR-C satellite program uses 16U CubeSats to demonstrate responsive, multi-mission capabilities, including testing two-way communications with ground devices and exploring novel tactical applications for small satellites. This program is the third in a series of missions to prove the effectiveness and versatility of CubeSat technology for the DoW.
* The CANVAS SmallSat mission developed by University of Colorado Boulder, is a NASA sponsored payload that will study the effects of lightning generated Very Low Frequency (VLF) waves on Earth's inner radiation belt.
* ASTRA-HyRAX, built by Auburn University and funded by the Army's Space and Missile Defense Command, is the newest mission under development in AUSSP. The mission aims to use a hybrid retro directive array (HRA) payload developed at Auburn to characterize the direction of signals from targets of opportunity.
* AggieSat6 is developed by students at Texas A&M University, in partnership with the Air Force Research Laboratory, to demonstrate new space domain awareness technology for tracking other satellites using commercial off-the-shelf components. The results from the payloads will be collected after the on-orbit test period is complete and will be fed back into various development pipelines for future capabilities.
Space Systems Command is the U.S. Space Force field command responsible for acquiring, developing, and delivering resilient capabilities to outpace emerging threats and protect our Nation's strategic advantage in, from, and to space. SSC manages a $15.6 billion annual space acquisition budget for the Department of War, working with joint forces, industry partners, government agencies, academia, and allied nations.
* * *
Original text here: https://www.ssc.spaceforce.mil/Newsroom/Article/4453711/us-space-force-launches-dow-stp-s29a-mission-delivers-experimental-and-research
President Trump Issues Statement on National Sexual Assault Awareness Month
WASHINGTON, April 8 -- President Trump issued the following statement on April 7, 2026, on National Sexual Assault Awareness Month:* * *
This National Sexual Assault Awareness Month, my Administration pledges to eradicate sexual assault and all forms of violence from our Nation by securing our border, deporting violent criminals, and restoring law and order in our cities.
In an unconscionable betrayal of American safety and sovereignty, the previous administration empowered a violent wave of criminal illegal aliens to invade our Nation through a wide-open southern border. Radical left-wing ... Show Full Article WASHINGTON, April 8 -- President Trump issued the following statement on April 7, 2026, on National Sexual Assault Awareness Month: * * * This National Sexual Assault Awareness Month, my Administration pledges to eradicate sexual assault and all forms of violence from our Nation by securing our border, deporting violent criminals, and restoring law and order in our cities. In an unconscionable betrayal of American safety and sovereignty, the previous administration empowered a violent wave of criminal illegal aliens to invade our Nation through a wide-open southern border. Radical left-wingprosecutors turned our streets into warzones by allowing rapists and other criminals to walk free from punishment and terrorize innocent Americans. Violent predators were put first; the American people were put last; and women, children, and families were left terrified in their communities. These disastrous policies led to a preventable rise in sexual assaults across our country. But since I returned to office, my Administration has swiftly reversed these heinous trends and made tremendous strides in eliminating the scourge of sexual assault.
As President, I immediately took action to end the invasion of violent illegal criminals pouring through our southern border and dismantle the human trafficking rings that have broken up families, abused women, and destroyed communities. I initiated the largest mass deportation operation in American history to remove the worst of the worst criminals, rapists, gang members, and human smugglers who have wreaked havoc across our Nation. And I deployed federal personnel and law enforcement resources to secure America's most dangerous cities.
Under my Administration, our southern border has been sealed, and dangerous sexual offenders are no longer being unleashed into our country. Thousands of rapists have been prosecuted and removed from our streets, and our Nation has seen reductions in sexual assaults and all forms of violent crime. America is now safer than it has been in over a century--and our work is only just beginning.
This month, we stand with every survivor of sexual assault, and we pledge to never waver in our fight to protect our people and communities. We will not rest until every city in America is safe, every victim receives justice, and every sexual predator is prosecuted to the fullest extent of the law.
* * *
Original text here: https://www.whitehouse.gov/briefings-statements/2026/04/presidential-message-on-national-cancer-control-month/
FDA Office of Inspections & Investigations Issues Warning Letter to Life Plus Style Gourmet
WASHINGTON, April 8 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Life Plus Style Gourmet LLC from its Office of Inspections and Investigations:* * *
Recipient: Ganesh Deivanayagam, CEO, Life Plus Style Gourmet LLC, 170 Express St, Plainview, NY 11803, United States, (b)(6), (b)(7)(C), praveen@lpsgourmet.com
Issuing Office: Office of Inspections and Investigations, United States
WARNING LETTER
RE: CMS# 724263
Dear Mr. Ganesh Deivanayagam:
On January 27, 2026, through January 29, 2026, the Food and Drug Administration ... Show Full Article WASHINGTON, April 8 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Life Plus Style Gourmet LLC from its Office of Inspections and Investigations: * * * Recipient: Ganesh Deivanayagam, CEO, Life Plus Style Gourmet LLC, 170 Express St, Plainview, NY 11803, United States, (b)(6), (b)(7)(C), praveen@lpsgourmet.com Issuing Office: Office of Inspections and Investigations, United States WARNING LETTER RE: CMS# 724263 Dear Mr. Ganesh Deivanayagam: On January 27, 2026, through January 29, 2026, the Food and Drug Administration(FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Life Plus Style Gourmet LLC located at 170 Express St., Plainview, NY 11803-2405. We also conducted inspections from September 12, 2022, through October 14, 2022, and October 26, 2023, through December 12, 2023. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.
The FSVP regulation requires that importers perform certain risk-based activities to verify that human and/or animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA's FSVP web page at https://www.fda.gov/food/food-safety-modernization-act-fsma/fsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.
During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import except foods from the foreign supplier (b)(4) located in (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.
At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.
We acknowledge receipt of your response, dated February 13, 2026, in which you stated you are nominating your compliance manager from your (b)(4) to take charge for developing your FSVP for the foods you import. You also stated you shall commence this work immediately and be able to have files in order in the next 4 - 6 weeks. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.
Your significant violations of the FSVP regulation are as follows:
* You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, with the exception of the products imported from the foreign supplier (b)(4) located in (b)(4).
The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.
This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http://www.accessdata.fda.gov/cms_ia/ialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).
You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.
Please send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley. Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS # 724263 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.
Sincerely,
/S/ CDR Joseph S. Tomao, Program Division Director, Division of Northeast Imports
* * *
Original text here: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/life-plus-style-gourmet-llc-724263-03052026
FDA Center for Tobacco Products Issues Warning Letter to Global Tobacco
WASHINGTON, April 8 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Global Tobacco, LLC from its Center for Tobacco Products:* * *
Recipient: Global Tobacco, LLC, 2861 Congressman Lane, Suite 300, Dallas, TX 75220, United States
Issuing Office: Center for Tobacco Products, United States
WARNING LETTER
To Whom It May Concern:
The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Global Tobacco, LLC imports, sells and/or distributes nicotine ... Show Full Article WASHINGTON, April 8 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Global Tobacco, LLC from its Center for Tobacco Products: * * * Recipient: Global Tobacco, LLC, 2861 Congressman Lane, Suite 300, Dallas, TX 75220, United States Issuing Office: Center for Tobacco Products, United States WARNING LETTER To Whom It May Concern: The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Global Tobacco, LLC imports, sells and/or distributes nicotinepouch products to customers in the United States.
Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. Sec. 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. Sec. 387a(b)) and 21 C.F.R. Sec. 1100.1, and are required to be in compliance with the requirements in the FD&C Act.
Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA's jurisdiction to products "containing nicotine from any source," not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of "tobacco product" under section 201(rr) of the FD&C Act (21 U.S.C. Sec. 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https://www.fda.gov/tobacco-products/ctp-newsroom/requirements-products-made-non-tobacco-nicotine-take-effect-april-14.
Generally, to be legally marketed in the United States, the FD&C Act requires "new tobacco products" to have a premarket authorization order in effect. A "new tobacco product" is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. Sec. 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. Sec. 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. Sec. 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. Sec. 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. Sec. 387e(j)(3)).
New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded
FDA has determined that you import and offer for sale or distribution to customers in the United States the following nicotine pouch products that lack a marketing authorization order: RUSH Mango Freeze 12MG.
The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. Sec. 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. Sec. 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.
Conclusion and Requested Actions
FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA's discretion.
For a list of products that received marketing granted orders, please visit our website: https://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/tobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.
It is your responsibility to ensure that all tobacco products you sell and/or distribute in the United States and all related labeling and/or advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA's implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. Sec. 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and/or injunction. However, this Warning Letter does not constitute "written notice" for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and/or misbranded may be detained or refused admission.
The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.
Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and/or distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA's homepage at http://www.fda.gov.
Please note your reference number, ER2601437, in your response and direct your response to the following address:
DEM-WL Response, Office of Compliance and Enforcement
FDA Center for Tobacco Products
c/o Document Control Center
Building 71, Room G335
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.
Sincerely,
/S/ John E. Verbeten, Director, Office of Compliance and Enforcement, Center for Tobacco Products
* * *
Original text here: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/global-tobacco-llc-725103-03312026
FDA Center for Devices & Radiological Health Issues Warning Letter to Medline Industries
WASHINGTON, April 8 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Medline Industries LP from its Center for Devices and Radiological Health:* * *
Recipient: Jim Boyle, CEO, Medline Industries, LP, 3 Lakes Drive, Northfield, IL 60093, United States, JBoyle@medline.com
Issuing Office: Center for Devices and Radiological Health, United States
WARNING LETTER
CMS # 723866
Dear Mr. Boyle:
During an inspection of your firm, Medline Industries, LP (NAMIC Division), located at 10 Glens Falls Tech Park, Glen Falls, NY 12801, ... Show Full Article WASHINGTON, April 8 -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Medline Industries LP from its Center for Devices and Radiological Health: * * * Recipient: Jim Boyle, CEO, Medline Industries, LP, 3 Lakes Drive, Northfield, IL 60093, United States, JBoyle@medline.com Issuing Office: Center for Devices and Radiological Health, United States WARNING LETTER CMS # 723866 Dear Mr. Boyle: During an inspection of your firm, Medline Industries, LP (NAMIC Division), located at 10 Glens Falls Tech Park, Glen Falls, NY 12801,from December 1, 2025 through December 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and assembles numerous medical devices into Cardiovascular Procedure Kits to include (but not limited to) NAMIC brand Angiographic Control Syringes and manifolds intended to be used for the intra-arterial or intravenous administration of radiographic contrast media. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. Sec. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.
Quality System Regulation Violations
This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. Sec. 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.
We received a response from Mr. Richard Kalita, Senior Manager of Quality Assurance, dated January 13, 2026, and February 27, 2026, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:
1. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).
Specifically:
A. Your firm failed to implement section 5.8.4 of your "Internal Corrective-Preventive Action Procedure (CAPA)" (SOP-00022; Rev. 40), which states "***[the] degree of corrective and preventive action taken to eliminate or minimize actual or potential nonconformities must be appropriate to the magnitude of the problem and commensurate with the risks encountered***", in that your firm did not take actions commensurate with risk for NAMIC Angiographic Control Syringes in the field for which CAPA-01872 was opened due to an increase in complaints in June 2023 regarding disconnection from manifolds you attributed to the presence of excess silicone. Your Health Hazard Evaluation (HHE) Qual-124366 dated June 11, 2024, determined the risk was low, which is inconsistent with your design failure modes and effectiveness analysis (dFMEA) (RA2022047; Rev. 4) which identified "air embolism" as the highest severity issue for loose connections. Your firm's corrective actions only included scrapping devices in inventory and increasing the cleaning frequency of the (b)(4) machine to prevent excess silicone from migrating to the luer connector, despite receiving 221 complaints and filing 177 MDRs for the disconnection of the NAMIC Angiographic Control Syringes from manifolds which impact patients and clinicians, including one (1) MDR # 3015910259-2025-00109 involving the injection of air into a patient (Complaint # (b)(4) dated (b)(4)) and one (1) MDR # 3015910259-2024-00045 involving biohazard exposure of a clinician (Complaint # (b)(4) dated (b)(4)).
B. Your firm failed to implement section 5.19 of your "Internal Corrective-Preventive Action Procedure (CAPA)" (SOP-00022; Rev. 47; Effective: 11/1/25), in that "***while in the effectiveness check stage and either the effectiveness check failed or additional root causes or problems are identified; the CAPA may be routed back to a previous phase or an additional CAPA may be opened at the discretion of the CRB [CAPA Review Board]. Risk and containment activities must be considered when moving the CAPA to a previous phase***". Your firm did not execute any of the above actions for CAPA-01872 when trending data revealed, as early as Quarter 1 of 2025, that the complaints per million (CPM) of NAMIC Angiographic Control Syringes manufactured post-corrective action was at 16.90 CPM followed by 16.44 CPM in Quarter 2 and 26.81 CPM in Quarter 3, all of which was above the 15.98 CPM threshold for complaints received for disconnections established in the verification of effectiveness plan (VOE AI# (b)(4) to start 1/15/25; Updated 8/1/25). Moreover, the total rate of complaints, including devices manufactured before and after the implementation of the corrective action (starting January 15, 2025) and for product where the manufacturing date is unknown, was 39.95 CPM, 31.62 CPM, and 59.27 CPM for Quarters 1, 2 and 3 of 2025, respectively.
We reviewed your firm's response and conclude that it is not adequate. In your January 13, 2026, response, your firm acknowledged that the corrective action was not effective, closed CAPA-01872, and opened a new CAPA-02612 to further investigate the issue. You also communicate a plan to issue a field correction with a safety notice to all customers who have received or will receive NAMIC Angiographic Control Syringes, based on a HHE (Qual-156459) of post-market data from June 2023 to December 2025, to alert them about the unwinding issue and provide reinforced instructions and additional guidance. You further state that you plan to develop (b)(4) syringe solution currently undergoing verification with production targeted to begin in (b)(4) and proposed that a field notice rather than a full product removal was appropriate given the effectiveness of prior communications, the upcoming alternative solution, and prevention of a market shortage.
In your latest response on February 27, 2026, you state that you updated your HHE (Qual-156459; Approved 2/26/26) to reflect your revised plan to conduct a removal of NAMIC Angiographic Control Syringes based on multiple discussions with the agency regarding your recall strategy. This HHE reports a total CPM for the syringe/ manifold disconnection issue from June 2023 to February 19, 2026, as 62.62 CPM (250 complaints out of (b)(4) syringes manufactured ending (b)(4)). On March 13, 2026, an 806 Report was submitted to the agency for the removal of these devices ((b)(4)).
You also indicate that you initiated an additional CAPA-02627 under which you conducted a systemic review of all open CAPAs and trained personnel on an updated CAPA procedure (SOP-00022) which requires more frequent post-market data reviews per established guidance. The targeted completion date for CAPA-02627 is June 30, 2026.
With regards to CAPA-02612, no information was provided on when you anticipate a new investigation will be completed to determine the cause(s) of the disconnections between the syringes and manifolds to assure your actions are timely and commensurate with risk of this issue. Furthermore, no assurance was provided that the scope of the product removal will include affected devices manufactured both before and after the corrective action (April 17, 2024) since the corrective action was found to be ineffective. Furthermore, the manufacturing quantities documented in your updated HHE fall short of the nearly (b)(4) syringes your Senior Director of Quality stated were manufactured (approximately (b)(4) devices from (b)(4) to (b)(4) and nearly (b)(4) devices from (b)(4) to (b)(4)) in that it states that only (b)(4) syringes were manufactured through (b)(4), resulting in 62.62 CPM (250 complaints), without defining the manufacturing start date of affected products. The HHE also incorrectly specifies a corrective action start date of June 2024 instead of April 16, 2024, as specified in CAPA-01872.
With regards to CAPA-02627, you did not identify actions that assure that employees will follow your corrective action procedure to route the CAPA back to a previous phase or open an additional CAPA as soon as it is evident that corrective actions are not effective, as was the case in (b)(4) of 2025 when your complaint analysis data showed that the CPM for syringe and manifold disconnections was above the established CPM thresholds.
Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and/or corrective actions, including any supporting evidence.
2. Failure to establish and maintain schedules for the adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met, as required by 21 CFR 820.70(g)(1).
Specifically, your firm failed to implement sections 6.2.2 ((b)(4) Cleaning) and 6.3 (General Requirements) of your "GN 010 - Manufacturing Cleaning Procedure" (NMC-00228; Rev. 7; Effective: 5/2/25) which state "a top-to-bottom cleaning of the controlled environments will be conducted, at minimum, (b)(4)***The cleaning shall also include all equipment not routinely cleaned by operators***" and "***Always clean the (b)(4) first and work toward the (b)(4) of cleaning with the (b)(4) being last***," respectively, of controlled environments such as the clean rooms where you manufacture various Angiographic and Radiology Syringes. In addition, the corresponding forms titled "(b)(4) Cleaning Schedule and Sign-off Sheet" form (NMC-00228-F-00001; Rev. 2) and "(b)(4) Cleaning Schedule and Sign-off Sheet" (NMC-00228-F-00002; Rev.1) are inadequate because they fail to ensure consistent implementation of sections 6.2.2 and 6.3 of NMC-00228 due to absence of specific instructions requiring the cleaning of top of manufacturing equipment as is included for the cleaning of vents, ceiling lights, walls, benches, cabinets, fixtures, etc. For example, on December 1, 2025, the investigator observed a visible accumulation of particulate on the top of manufacturing equipment in cleanrooms including the (b)(4) syringe manufacturing machine (ID # 90303527), (b)(4) machine (ID # 90306846), (b)(4) manufacturing machine (ID # 90308616), and (b)(4) machine (Asset # 8974). There have been approximately 114 complaints regarding foreign matter or hair in the package or device from December 2023 to at least December 1, 2025.
We reviewed your firm's response and conclude that it is not adequate. In your January 13, 2026, response, you state you performed immediate ad-hoc cleaning of all equipment to remove observed particulate matter, established preventative maintenance schedules based on (b)(4) of monitoring data, and updated the cleaning and preventative maintenance procedures (NMC-00228 and NMC-00171) to formalize these requirements followed by training under CAPA-02518. Additionally, you state you developed an ad-hoc cleaning procedure (NMC-01120) and addressed air filtration concerns by installing (b)(4) indicators around all cleanroom (b)(4) vents to ensure proper clearance, repaired damaged vents, and updated your environmental control procedure (NMC-00233) to include inspection and clearance requirements. You also determined that validation of the cleaning process was not required.
In your latest response on February 27, 2026, you state you conducted a comprehensive review of the cleanroom manufacturing environments and identified improvement opportunities but not any risks. The target completion for these additional actions is April 30, 2026, and the target completion date of CAPA-02518 is July 17, 2026.
However, there were no corrective actions identified to assess the impact of products in the field and inventory for products which have been manufactured in these cleanrooms since the last documented cleaning of equipment tops on November 26, 2023, including review of the manufacturing dates of products referenced in the 114 complaints received for foreign matter or hair since this date as a part of the respective complaint investigations. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and/or corrective actions, including any supporting evidence.
3. Failure to establish and maintain procedures for verifying the device design. Design verification shall confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).
Specifically, your firm's design verification conducted under "Design Verification Protocol Polycarbonate Female Luer ISO 80369-7" (P017333; Rev. B; Approved: 10/7/20) with resulting "Design Verification Report Polycarbonate Female Luer ISO 80369-7" (P017334; Rev. A; Approved: 6/30/20) fails to demonstrate that the polycarbonate female luer connector components of your Fluid Management product lines (e.g., stopcock product family, manifold product family, disposable transducer product family, Y adaptor, etc.), which underwent changes to their threads and taper dimensions to become BS EN ISO 80369-7 compliant, meet the dimensional and functional testing requirements specified in this standard. For example, there was no documentation in the protocol (or elsewhere) on why design verification testing was only performed on a single female luer connector (Part # 24644210) and not any of the other (b)(4) connectors listed in the "Scope" section of this protocol which were also impacted by this design change. Moreover, this solely tested connector is not included in the final version of your "Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4" (Approved: 9/7/22) which captures all luer connectors affected by this design change.
We reviewed your firm's response and conclude that it is not adequate. In your January 13, 2026 response, you state you revised the design verification procedure (NMC-00155) to require documentation of part selection rationale, added product configuration tables and guidance for recording representative SKU selection and rationale for selection in the Design Verification Protocol Template (NMC-00155-F-00001), and amended design change file QUAL-66717 to include the missing justification for part selection under CAPA-02610.
In your latest response on February 27, 2026, you state you conducted a comprehensive review of all design changes from (b)(4) to present that required design verification testing and uncovered four (4) instances of insufficient documentation of part rationale which will require protocol updates with appropriate justification. The target completion of CAPA-02610 is June 1, 2026.
However, review of the "Unit Rationale" provided revealed that it fails to explain how design verification testing of part number 41338202 covers anything beyond the manifold product family, such as the stopcock product family, disposable transducer product family, and Y adaptor of the Fluid Management product lines which were in the scope of the Design Verification. Moreover, this rationale does not explain why this part number was not listed in the final version of your "Design Change Analysis Form (DCAF) for ISO 80369-7 Compliance for Male and Female Luer Connectors (P017104) QUAL-66717 Rev. 4" (Approved: 9/7/22) meant to capture all the luer connectors affected by this design change. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and/or corrective actions, including any supporting evidence.
Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.
Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.
On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection on December 1, 2025 to December 12, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https://www.fda.gov/medical-devices/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp/quality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.
Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and/or corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and/or corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and/or corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.
Your firm's response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, "CMS Case 723866" when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.
Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.
Sincerely,
/S/ Barbara A. Marsden, Director, Office of Regulatory Programs, Office of Product Evaluation and Quality, Center for Devices and Radiological Health
CC: Bradley R. Pratt, Sr. Director of Manufacturing Operations, BPratt@medline.com
* * *
Original text here: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medline-industries-lp-723866-03252026
Department of Justice: California Man Pleads Guilty to Orchestrating $270M Medication Reimbursement Fraud Scheme
WASHINGTON, April 8 -- The U.S. Department of Justice issued the following news release on April 7, 2026:* * *
California Man Pleads Guilty to Orchestrating $270M Medication Reimbursement Fraud Scheme
A California man pleaded guilty yesterday to submitting nearly $270 million in fraudulent claims over an 11-month span to California's Medicaid program (Medi-Cal) for expensive prescription drugs that were medically unnecessary and, in many instances, not provided to the purported recipients.
The Department of Justice announced this case and two others in support of President Trump's Task Force ... Show Full Article WASHINGTON, April 8 -- The U.S. Department of Justice issued the following news release on April 7, 2026: * * * California Man Pleads Guilty to Orchestrating $270M Medication Reimbursement Fraud Scheme A California man pleaded guilty yesterday to submitting nearly $270 million in fraudulent claims over an 11-month span to California's Medicaid program (Medi-Cal) for expensive prescription drugs that were medically unnecessary and, in many instances, not provided to the purported recipients. The Department of Justice announced this case and two others in support of President Trump's Task Forceto Eliminate Fraud at a press conference in Washington today.
"Thanks to the leadership of President Donald Trump, the Department, working closely with the Task Force to Eliminate Fraud, is supercharging efforts to take down every fraudster and bring them to justice," said Acting Attorney General Todd Blanche. "In one day, the Department prosecuted the theft of a half-billion in taxpayer dollars. All those ripping off the American people are on notice."
"The defendant was a repeat fraudster who caused Medi-Cal, a program designed to help those in need, to be billed nearly $270 million for expensive and medically unnecessary medications," said Assistant Attorney General A. Tysen Duva of the Justice Department's Criminal Division. "He and his co-schemers stole over $178 million through false and fraudulent claims for these medications, lining their own pockets with public funds. The Criminal Division will aggressively prosecute those who defraud Medicaid and exploit taxpayer-funded benefit programs."
"This defendant used a public health program as his personal piggy bank," said First Assistant U.S. Attorney Bill Essayli of the Central District of California. "This guilty plea should send a message that this administration -- consistent with the President's war on fraud -- will not turn a blind eye while criminals fleece taxpayers."
"Schemes that bill Medicaid for costly drugs that patients never needed or received threaten the integrity of the program," said Acting Deputy Inspector General for Investigations Scott J. Lampert of the U.S. Department of Health and Human Services, Office of Inspector General (HHS-OIG). "This plea shows our firm resolve, alongside our law enforcement partners, to exposing such fraud operations, ensuring those responsible are held accountable, and safeguarding taxpayer-funded health care programs."
According to court documents, Paul Randall, 66, of Orange, along with pharmacist and pharmacy owner Kyrollos Mekail, 37, of Moreno Valley, and nurse practitioner Patricia Anderson, 58, of West Hills, exploited Medi-Cal's suspension of its requirement that health care providers obtain prior authorization before providing certain medications at the beginning of 2022. Medi-Cal temporarily suspended the requirement as part of a transition to a new payment system. Using a business called Monte Vista Pharmacy, which Mekail owned, Randall and his co-schemers billed Medi-Cal tens of millions of dollars per month for purportedly dispensing high-reimbursement drugs containing cheap, generic ingredients that were manufactured in unique dosages, combinations or package quantities and were not included in the applicable maximum price lists that cap Medi-Cal reimbursements.
In furtherance of the scheme, Randall paid illegal kickbacks to patient marketers in exchange for Medi-Cal beneficiary information and thereafter paid illegal kickbacks to Anderson to sign pre-filled prescriptions for 19 high-reimbursement, non-contracted, generic drugs. Anderson never met the patients, reviewed their medical records or otherwise determined that the medications were medically necessary before signing the prescriptions. The medications, which included pain creams and Folite tablets, a vitamin available over the counter, were billed for thousands of dollars each, including approximately $13,424 for one prescription of meloxicam 5 mg, a generic drug that typically costs between $5 and $25 for a 30-day supply in larger dosages.
Randall received a portion of Monte Vista's reimbursements from Medi-Cal, at times equaling approximately 40% of Monte Vista's profit from the false and fraudulent claims. Randall admitted in his plea agreement that he caused at least $269,120,829 in false and fraudulent claims to Medi-Cal from May 2022 to April 2023, of which Medi-Cal paid at least approximately $178,746,556. Randall also admitted that he committed the offense while on release in another criminal case.
Randall and others laundered their illicit proceeds by transferring the money to a third party to pay kickbacks to Anderson in an attempt to conceal the crime from law enforcement.
In his plea agreement, Randall agreed to forfeit property obtained from the fraud, including bank account balances exceeding $17 million, three vehicles, seven real properties, and sports memorabilia. To date, the government has seized approximately $126.5 million in assets that Randall and his co-schemers accumulated from the scheme, including $111 million in bank funds and securities, nine luxury vehicles totaling approximately $1 million, nine luxury real properties totaling approximately $13.5 million, and more than $1 million worth of sports memorabilia.
Randall pleaded guilty to one count of wire fraud. He is scheduled to be sentenced on August 3 and faces a maximum penalty of 30 years in prison. A federal district court judge will determine any sentence after considering the U.S. Sentencing Guidelines and other statutory factors.
Relatedly, in August 2024, Mekail pleaded guilty to two counts of health care fraud and awaits sentencing. In April 2025, Anderson pleaded guilty to two counts of health care fraud and also awaits sentencing.
The FBI, HHS-OIG, and the California Department of Justice are investigating the case.
Assistant Chief Niall M. O'Donnell and Trial Attorney Siobhan M. Namazi of the Criminal Division's Fraud Section and Assistant U.S. Attorney Roger A. Hsieh for the Central District of California are prosecuting the case. Assistant U.S. Attorney James E. Dochterman for the Central District of California's Asset Forfeiture and Recovery Section is handling asset forfeiture matters in this case.
The Fraud Section leads the Criminal Division's efforts to combat health care fraud through the Health Care Fraud Strike Force Program. Since March 2007, this program, currently comprised of eight strike forces operating in federal districts across the country, has charged more than 6,200 defendants who collectively have billed federal health care programs and private insurers more than $45 billion. In addition, the Centers for Medicare & Medicaid Services, working in conjunction with the Office of the Inspector General for the Department of Health and Human Services, are taking steps to hold providers accountable for their involvement in health care fraud schemes. More information can be found at www.justice.gov/criminal-fraud/health-care-fraud-unit.
* * *
Original text here: https://www.justice.gov/opa/pr/california-man-pleads-guilty-orchestrating-270m-medication-reimbursement-fraud-scheme
Department of Justice: Business Owner Sentenced to Over Four Years in Prison for $100M COVID-19 Tax Credit Scheme
WASHINGTON, April 8 -- The U.S. Department of Justice issued the following news release on April 7, 2026:* * *
Business Owner Sentenced to Over Four Years in Prison for $100M COVID-19 Tax Credit Scheme
Caused IRS to Pay Out $33 Million in Undeserved Credits
*
A Nevada woman was sentenced yesterday to 54 months in prison and three years of supervised release for conspiring to defraud the United States by fraudulently claiming nearly $100 million in COVID-19 related employment tax credits.
The Department of Justice announced this case and two others in support of President Trump's Task Force ... Show Full Article WASHINGTON, April 8 -- The U.S. Department of Justice issued the following news release on April 7, 2026: * * * Business Owner Sentenced to Over Four Years in Prison for $100M COVID-19 Tax Credit Scheme Caused IRS to Pay Out $33 Million in Undeserved Credits * A Nevada woman was sentenced yesterday to 54 months in prison and three years of supervised release for conspiring to defraud the United States by fraudulently claiming nearly $100 million in COVID-19 related employment tax credits. The Department of Justice announced this case and two others in support of President Trump's Task Forceto Eliminate Fraud at a press conference in Washington today.
"Thanks to the leadership of President Donald Trump, the Department, working closely with the Task Force to Eliminate Fraud, is supercharging efforts to take down every fraudster and bring them to justice," said Acting Attorney General Todd Blanche. "In one day, the Department prosecuted the theft of a half-billion in taxpayer dollars. All those ripping off the American people are on notice."
According to court documents and statements made in court, Candies Goode-McCoy, formerly of Las Vegas, conspired with others to file tax returns seeking fraudulent refunds based on the employee retention credit and paid sick and family leave credit, credits which Congress created to aid struggling businesses during the COVID-19 global pandemic. From approximately June 2022 through September 2023, McCoy filed more than 1,200 tax returns for her own businesses and those of others, which falsely claimed these credits and sought refunds totaling more than $98 million.
In total, the IRS paid out approximately $33 million as a result of the scheme. Personally, Goode-McCoy received over $1.3 million in fraudulent refunds. She also received approximately $800,000 from clients for filing fraudulent returns. McCoy used the proceeds to pay for vacations, luxury cars and other luxury goods, and to gamble at casinos.
Goode-McCoy pleaded guilty to one count of conspiracy to defraud the government with respect to claims. In addition to the term of imprisonment, McCoy was ordered to pay the IRS $26,022,188 in restitution.
Assistant Attorney General A. Tysen Duva of the Justice Department's Criminal Division and First Assistant U.S. Attorney Sigal Chattah for the District of Nevada joined in the announcement.
IRS Criminal Investigation and the Treasury Inspector General for Tax Administration investigated the case.
Trial Attorney John C. Gerardi of the Criminal Division's Tax Section and Assistant U.S. Attorney Richard Anthony Lopez of the District of Nevada prosecuted the case.
* * *
Original text here: https://www.justice.gov/opa/pr/business-owner-sentenced-over-four-years-prison-100m-covid-19-tax-credit-scheme